-
PegBio’s Lead Product PB-119 Clears HKEX Hearing for Type 2 Diabetes and Obesity Treatment
•
On January 28, 2025, the Hong Kong Stock Exchange (HKEX) website showed that PegBio Co., Ltd., a Suzhou-based specialist in endocrine metabolism, has successfully passed the HKEX hearing. China International Capital Corporation (CICC) acted as the sole sponsor. Company OverviewPegBio was established in 2008 as a biotechnology company focused on…
-
PegBio Files for IPO on Hong Kong Stock Exchange
•
PegBio Co., Ltd., a specialist in endocrine metabolism based in Suzhou, has taken a significant step towards going public with an initial public offering (IPO) filing to the Hong Kong Stock Exchange (HKSE). While the price and other specific details of the offering are yet to be disclosed, the move…
